{"id":10826,"date":"2022-11-09T06:56:24","date_gmt":"2022-11-09T06:56:24","guid":{"rendered":"https:\/\/marylanddailygazette.com\/ulcerative-colitis-pipeline-analysis-110-companies-are-working-to-improve-the-treatment-space-delveinsight\/"},"modified":"2022-11-09T06:56:24","modified_gmt":"2022-11-09T06:56:24","slug":"ulcerative-colitis-pipeline-analysis-110-companies-are-working-to-improve-the-treatment-space-delveinsight","status":"publish","type":"post","link":"https:\/\/marylanddailygazette.com\/ulcerative-colitis-pipeline-analysis-110-companies-are-working-to-improve-the-treatment-space-delveinsight\/","title":{"rendered":"Ulcerative Colitis Pipeline Analysis: 110+ Companies are Working to Improve the Treatment Space | DelveInsight"},"content":{"rendered":"<p><a href=\"https:\/\/www.digitaljournal.com\/pr\/ulcerative-colitis-pipeline-analysis-110-companies-are-working-to-improve-the-treatment-space-delveinsight\">Ulcerative Colitis Pipeline Analysis: 110+ Companies are Working to Improve the Treatment Space | DelveInsight<\/a><\/p>\n<p><div><a href=\"https:\/\/marylanddailygazette.com\/wp-content\/uploads\/2022\/11\/G9Sg2r.png\" target=\"_blank\" rel=\"nofollow noopener\"><img decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Ulcerative Colitis Pipeline Analysis: 110+ Companies are Working to Improve the Treatment Space | DelveInsight\" src=\"https:\/\/marylanddailygazette.com\/wp-content\/uploads\/2022\/11\/G9Sg2r.png\" alt=\"Ulcerative Colitis Pipeline Analysis: 110+ Companies are Working to Improve the Treatment Space | DelveInsight\" width=\"225\"><\/a><\/div>\n<p>DelveInsight\u2019s, \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">Ulcerative Colitis Pipeline Insight<\/a>, 2022,\u201d report provides comprehensive insights about 110+ companies and 110+ pipeline drugs in Ulcerative Colitis (UC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p><strong>Key takeaways from Ulcerative Colitis Pipeline Insight Report<\/strong><\/p>\n<ul>\n<li>DelveInsight\u2019s Ulcerative Colitis Pipeline report depicts a robust space with 110+ active players working to develop 110+ pipeline therapies for Ulcerative Colitis.<\/li>\n<li>The leading Ulcerative Colitis Companies such as Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research &amp; Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, GlaxoSmithKline, Galapagos, Celgene, Gossamer Bio, Eisai, UCB, Suzhou Connect Biopharmaceuticals, Landos Biopharma, Seres Therapeutics, Abivax, Genentech, ParaTech A\/S, I-Mab Biopharma, Sublimity Therapeutics Holdco, Reistone Biopharma, Qu Biologics, PurGenesis Technologies, Protagonist Therapeutics, Pfizer, Palobiofarma, Novartis Pharmaceuticals, Bristol-Myers Squibb, Bridge Biotherapeutics, Amgen, Allergan, Applied Molecular Transport, AbGenomics International, Protalix BioTherapeutics, LTT Bio-Pharma Co Ltd, Dongwha pharma, Seres Therapeutics, Innovation Pharmaceuticals, Holy Stone Healthcare, SLA Pharma, OSE Immunotherapeutics, Bridge Biotherapeutics, Mitsubishi Tanabe Pharma, Sterna Biologicals, Mesoblast, Oncostellae, First Wave Bio, Oppilan Pharma, NeuClone, Morphic Therapeutic, Metacrine, LG Chem, Koutif Therapeutics, Kiniksa Pharmaceuticals, Avaxia Biologics, Algernon Pharmaceuticals, Akeso Biopharma, Kaleido Biosciences, Rebiotix, and many more.<\/li>\n<li>Promising Ulcerative Colitis therapies such as ABX464, adalimumab, endoscopy, Budesonide MMX\u00ae 6 mg, tralokinumab, BBT-401-1S, Filgotinib, PTM filgotinib, Mesalazine, and others<\/li>\n<li>The companies and academics are working to assess challenges and seek opportunities that could influence Ulcerative Colitis R&amp;D. The therapies under development are focused on novel approaches to treat\/improve Ulcerative Colitis.<\/li>\n<li>In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ulcerative Colitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.<\/li>\n<\/ul>\n<p><strong>Request a sample and discover the recent advances in Ulcerative Colitis treatment @ <a href=\"https:\/\/www.delveinsight.com\/sample-request\/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">Ulcerative Colitis Pipeline Report<\/a><\/strong><\/p>\n<p><strong>Ulcerative Colitis Overview<\/strong><\/p>\n<p>Ulcerative colitis is a chronic disease of the large intestine, in which the lining of the colon become inflamed and develops tiny open sores or ulcers. Those ulcers produce pus and mucous, which causes abdominal pain. It usually begins in the rectum and spreads upwards. The inflammation causes bowel to move its content rapidly and empty frequently. Ulcerative colitis begins gradually and become worse over the period of time. Ulcerative colitis also known as inflammatory bowel disease. Ulcerative colitis symptoms range from mild to severe and varies among affected people. The predominant symptoms in ulcerative colitis is diarrhea, which can be associated with the discharge of blood in the stool.<\/p>\n<p><strong>Latest Breakthroughs of Ulcerative Colitis Treatment Landscape<\/strong><\/p>\n<ul>\n<li>Mirikizumab is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of interleukin 23. Mirikizumab is being studied for the treatment of immune-mediated diseases, including ulcerative colitis and Crohn\u2019s disease.<\/li>\n<li>Risankizumab is an antagonistic anti-CD40 antibody. The CD40-CD40L pathway may play a major role in immune disease such as lupus nephritis, Crohn\u2019s disease and ulcerative colitis.<\/li>\n<li>Etrasimod is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5. It is being investigated for a range of immuno-inflammatory diseases, including ulcerative colitis, Crohn\u2019s disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata.<\/li>\n<\/ul>\n<p><strong>Find out more about Ulcerative Colitis Medication @ <a href=\"https:\/\/www.delveinsight.com\/sample-request\/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">Ulcerative Colitis Treatment<\/a><\/strong><\/p>\n<p><strong>Ulcerative Colitis Emerging Drugs<\/strong><\/p>\n<ul>\n<li>Mirikizumab: Eli Lilly and Company<\/li>\n<li>Risankizumab: AbbVie<\/li>\n<li>Etrasimod: Pfizer<\/li>\n<\/ul>\n<p><strong>DelveInsight\u2019s Ulcerative Colitis Pipeline Report covers around 110+ products under different phases of clinical development like<\/strong><\/p>\n<ul>\n<li>Late stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p><strong>Learn more about the novel and emerging Ulcerative Colitis pipeline therapies @ <a href=\"https:\/\/www.delveinsight.com\/sample-request\/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">Ulcerative Colitis Clinical Trials<\/a><\/strong><\/p>\n<p><strong>Scope of the Ulcerative Colitis Pipeline Report<\/strong><\/p>\n<ul>\n<li>Coverage- Global<\/li>\n<li>Ulcerative Colitis Assessment by Product Type<\/li>\n<li>Ulcerative Colitis Assessment by Stage and Product Type<\/li>\n<li>Ulcerative Colitis Assessment by Route of Administration<\/li>\n<li>Ulcerative Colitis Assessment by Stage and Route of Administration<\/li>\n<li>Ulcerative Colitis Assessment by Molecule Type<\/li>\n<li>Ulcerative Colitis Assessment by Stage and Molecule Type<\/li>\n<li>Ulcerative Colitis Companies- Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research &amp; Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, GlaxoSmithKline, Galapagos, Celgene, Gossamer Bio, Eisai, UCB, Suzhou Connect Biopharmaceuticals, Landos Biopharma, Seres Therapeutics, Abivax, Genentech, ParaTech A\/S, I-Mab Biopharma, Sublimity Therapeutics Holdco, Reistone Biopharma, Qu Biologics, PurGenesis Technologies, Protagonist Therapeutics, Pfizer, Palobiofarma, Novartis Pharmaceuticals, Bristol-Myers Squibb, Bridge Biotherapeutics, Amgen, Allergan, Applied Molecular Transport, AbGenomics International, Protalix BioTherapeutics, LTT Bio-Pharma Co Ltd, Dongwha pharma, Seres Therapeutics, Innovation Pharmaceuticals, Holy Stone Healthcare, SLA Pharma, OSE Immunotherapeutics, Bridge Biotherapeutics, Mitsubishi Tanabe Pharma, Sterna Biologicals, Mesoblast, Oncostellae, First Wave Bio, Oppilan Pharma, NeuClone, Morphic Therapeutic, Metacrine, LG Chem, Koutif Therapeutics, Kiniksa Pharmaceuticals, Avaxia Biologics, Algernon Pharmaceuticals, Akeso Biopharma, Kaleido Biosciences, Rebiotix, and others.<\/li>\n<li>Ulcerative Colitis Therapies- ABX464, adalimumab, endoscopy, Budesonide MMX\u00ae 6 mg, tralokinumab, BBT-401-1S, Filgotinib, PTM filgotinib, Mesalazine, and others.<\/li>\n<\/ul>\n<p><strong>Dive deep into rich insights for drugs for Ulcerative Colitis treatment, visit @ <a href=\"https:\/\/www.delveinsight.com\/sample-request\/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">New Drug for Ulcerative Colitis Treatment<\/a><\/strong><\/p>\n<p><strong>Table of content<\/strong><\/p>\n<ol start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Ulcerative Colitis: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Ulcerative Colitis\u2013 DelveInsight\u2019s Analytical Perspective<\/li>\n<li>In-depth Commercial Assessment<\/li>\n<li>Ulcerative Colitis Collaboration Deals<\/li>\n<li>Late Stage Products (Preregistration)<\/li>\n<\/ol>\n<p>10. Mirikizumab: Eli Lilly and Company<\/p>\n<p>11. Late Stage Products (Phase III)<\/p>\n<p>12. Upadacitinib: AbbVie<\/p>\n<p>13. Mid Stage Products (Phase II\/III)<\/p>\n<p>14. TD-1473: Theravance Biopharma<\/p>\n<p>15. Mid Stage Products (Phase II)<\/p>\n<p>16. LYC-30937: Lycera<\/p>\n<p>17. Early Stage Products (Phase I\/II)<\/p>\n<p>18. Remestemcel-L: Mesoblast<\/p>\n<p>19. Early Stage Products (Phase I)<\/p>\n<p>20. OPL-002: Oppilan Pharma<\/p>\n<p>21. IND Stage Products<\/p>\n<p>22. SVT-1A710: Servatus<\/p>\n<p>23. Preclinical Stage Products<\/p>\n<p>24. ATH-001: Athos Therapeutics<\/p>\n<p>25. Discovery Stage Products<\/p>\n<p>26. NM 001: NuMedii<\/p>\n<p>27. Inactive Products<\/p>\n<p>28. Ulcerative Colitis Key Companies<\/p>\n<p>29. Ulcerative Colitis Key Products<\/p>\n<p>30. Ulcerative Colitis- Unmet Needs<\/p>\n<p>31. Ulcerative Colitis- Market Drivers and Barriers<\/p>\n<p>32. Ulcerative Colitis- Future Perspectives and Conclusion<\/p>\n<p>33. Ulcerative Colitis Analyst Views<\/p>\n<p>34. Ulcerative Colitis Key Companies<\/p>\n<p>35. Appendix<\/p>\n<p><strong>About Us<\/strong><\/p>\n<p>DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &amp; Acquisitions.<\/p>\n<p><span>Media Contact<\/span><br \/><strong>Company Name:<\/strong> DelveInsight Business Research LLP<br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"http:\/\/www.universalpressrelease.com\/?pr=ulcerative-colitis-pipeline-analysis-110-companies-are-working-to-improve-the-treatment-space-delveinsight&amp;type=pra\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=ulcerative-colitis-pipeline-analysis-110-companies-are-working-to-improve-the-treatment-space-delveinsight\" alt width=\"1px\" height=\"1px\"><\/p>\n<p>Published Tue, 08 Nov 2022 20:10:15 -0600<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ulcerative Colitis Pipeline Analysis: 110+ Companies are Working to Improve the Treatment Space | DelveInsight DelveInsight\u2019s, \u201cUlcerative Colitis Pipeline Insight, 2022,\u201d report provides comprehensive insights about 110+ companies and 110+ pipeline drugs in Ulcerative Colitis (UC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":10825,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts\/10826"}],"collection":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/comments?post=10826"}],"version-history":[{"count":0,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts\/10826\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/media\/10825"}],"wp:attachment":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/media?parent=10826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/categories?post=10826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/tags?post=10826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}